Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.

Peh, Keng Hee; Przybylski, Daniel J; Fallon, Michael J; Bergsbaken, Jason J; Hutson, Paul R; Yu, Menggang; Deming, Dustin A; Burkard, Mark E

Peh, Keng Hee; Przybylski, Daniel J; Fallon, Michael J; Bergsbaken, Jason J; Hutson, Paul R; Yu, Menggang; Deming, Dustin A; Burkard, Mark E.

Afiliação

Peh KH; University of Kentucky College of Pharmacy, Lexington, KY, United States.
Przybylski DJ; Northwestern Medicine, Chicago, IL, United States.
Fallon MJ; UW Health, Madison, WI, United States.
Bergsbaken JJ; UW Health, Madison, WI, United States.
Hutson PR; School of Pharmacy, University of Wisconsin - Madison, Madison, WI, United States.
Yu M; University of Wisconsin Carbone Cancer Center, Madison, WI, United States.
Deming DA; University of Wisconsin Carbone Cancer Center, Madison, WI, United States.
Burkard ME; Department of Medicine, Hematology/Oncology and McArdle Laboratories, University of Wisconsin, Madison, WI, United States.

J Oncol Pharm Pract ; 29(5): 1094-1102, 2023 Jul.

Article em En | MEDLINE | ID: mdl-35369813

Assuntos

Neoplasias; Medicina de Precisão; Humanos; Neoplasias/terapia; Neoplasias/tratamento farmacológico; Mutação; Terapia de Alvo Molecular

Palavras-chave

Precision medicine; health services research; molecular tumor board; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicina de Precisão / Neoplasias Tipo de estudo: Guideline / Observational_studies Limite: Humans Idioma: En Revista: J Oncol Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google